2025 Q2 -tulosraportti
193 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 490 | - | - | ||
| 10 | - | - | ||
| 1 | - | - | ||
| 4 725 | - | - | ||
| 6 542 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·38 min sitten · MuokattuThe event many biotech investors are watching at Circio Holding ASA is actually quite specific: The potential “trigger”: The Big Pharma feasibility study. In November 2025, Circio announced that they have started a fully funded feasibility study with a large global pharma company for their circRNA platform circVec. Circio + 1 This means in practice: Big Pharma tests the technology itself They pay for the experiments If the results are good → it can lead to a license or partnership This study tests circVec in AAV gene therapy. Why it can be a huge catalyst: Circio has shown: Up to 40× higher protein expression in heart Up to 50× higher expression in the eye in newer data from 2026. Much longer RNA half-life (stability) If the technology works really well, big pharma often buys the entire company. That's exactly what happened with Orna Therapeutics, which was acquired by Eli Lilly and Company. Who could this big pharma partner be?? 1. Eli Lilly and Company Why many guess Lilly: They recently acquired Orna Therapeutics (circular RNA platform). They are aggressively investing in next-generation RNA technology. They have the capital and strategy to quickly build an entire RNA area. Strategic logic: Orna focuses mostly on cell therapy (CAR-T). Circio’s circVec can be used for gene therapy and protein production. That could make Lilly a potential “circRNA platform owner”. 2. Moderna Why they might be interested: The entire company is built on RNA technology. They are actively looking for the next generation after mRNA. Circular RNA can have: longer stability longer protein production lower dose If circRNA proves stronger than mRNA in some applications, Moderna would almost be forced to acquire the technology quickly. 3. Roche Why Roche makes strategic sense: They invest heavily in gene therapy. They have many programs where protein expression is central. circRNA can potentially be used for in-vivo protein production. Roche has previously acquired smaller biotech platforms to strengthen their pipeline.
1 t sitten1 t sitten"Be greedy when others are fearful" Warren buffett. 😉
·1 t sittenThe last time we got news was on February 26th when it rose from 2.2 to 3.5 in a short time. There was a lot of hype around the stock which made it rise significantly. Now that time passes without news, it will naturally fall, as many simply take profit and sell off. But the most important thing is that despite no news for some time, we are at 3, which is still an increase of 36% since the last news. It can easily fall further in the next couple of days. Personally, I see it as a cheap buying opportunity. It will be exciting to hear what CEO Erik Wiklund has to say on the podcast on March 17th, and if things go well on March 18th at the LSX RNA Leaders Europe conference, I cannot see how the stock should fall next week. It is important to understand, however, that this stock is dependent on news, so if there are periods without news, it will fall, and then it's just about having patience.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
193 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·38 min sitten · MuokattuThe event many biotech investors are watching at Circio Holding ASA is actually quite specific: The potential “trigger”: The Big Pharma feasibility study. In November 2025, Circio announced that they have started a fully funded feasibility study with a large global pharma company for their circRNA platform circVec. Circio + 1 This means in practice: Big Pharma tests the technology itself They pay for the experiments If the results are good → it can lead to a license or partnership This study tests circVec in AAV gene therapy. Why it can be a huge catalyst: Circio has shown: Up to 40× higher protein expression in heart Up to 50× higher expression in the eye in newer data from 2026. Much longer RNA half-life (stability) If the technology works really well, big pharma often buys the entire company. That's exactly what happened with Orna Therapeutics, which was acquired by Eli Lilly and Company. Who could this big pharma partner be?? 1. Eli Lilly and Company Why many guess Lilly: They recently acquired Orna Therapeutics (circular RNA platform). They are aggressively investing in next-generation RNA technology. They have the capital and strategy to quickly build an entire RNA area. Strategic logic: Orna focuses mostly on cell therapy (CAR-T). Circio’s circVec can be used for gene therapy and protein production. That could make Lilly a potential “circRNA platform owner”. 2. Moderna Why they might be interested: The entire company is built on RNA technology. They are actively looking for the next generation after mRNA. Circular RNA can have: longer stability longer protein production lower dose If circRNA proves stronger than mRNA in some applications, Moderna would almost be forced to acquire the technology quickly. 3. Roche Why Roche makes strategic sense: They invest heavily in gene therapy. They have many programs where protein expression is central. circRNA can potentially be used for in-vivo protein production. Roche has previously acquired smaller biotech platforms to strengthen their pipeline.
- 1 t sitten1 t sitten"Be greedy when others are fearful" Warren buffett. 😉
- ·1 t sittenThe last time we got news was on February 26th when it rose from 2.2 to 3.5 in a short time. There was a lot of hype around the stock which made it rise significantly. Now that time passes without news, it will naturally fall, as many simply take profit and sell off. But the most important thing is that despite no news for some time, we are at 3, which is still an increase of 36% since the last news. It can easily fall further in the next couple of days. Personally, I see it as a cheap buying opportunity. It will be exciting to hear what CEO Erik Wiklund has to say on the podcast on March 17th, and if things go well on March 18th at the LSX RNA Leaders Europe conference, I cannot see how the stock should fall next week. It is important to understand, however, that this stock is dependent on news, so if there are periods without news, it will fall, and then it's just about having patience.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 490 | - | - | ||
| 10 | - | - | ||
| 1 | - | - | ||
| 4 725 | - | - | ||
| 6 542 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
193 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·38 min sitten · MuokattuThe event many biotech investors are watching at Circio Holding ASA is actually quite specific: The potential “trigger”: The Big Pharma feasibility study. In November 2025, Circio announced that they have started a fully funded feasibility study with a large global pharma company for their circRNA platform circVec. Circio + 1 This means in practice: Big Pharma tests the technology itself They pay for the experiments If the results are good → it can lead to a license or partnership This study tests circVec in AAV gene therapy. Why it can be a huge catalyst: Circio has shown: Up to 40× higher protein expression in heart Up to 50× higher expression in the eye in newer data from 2026. Much longer RNA half-life (stability) If the technology works really well, big pharma often buys the entire company. That's exactly what happened with Orna Therapeutics, which was acquired by Eli Lilly and Company. Who could this big pharma partner be?? 1. Eli Lilly and Company Why many guess Lilly: They recently acquired Orna Therapeutics (circular RNA platform). They are aggressively investing in next-generation RNA technology. They have the capital and strategy to quickly build an entire RNA area. Strategic logic: Orna focuses mostly on cell therapy (CAR-T). Circio’s circVec can be used for gene therapy and protein production. That could make Lilly a potential “circRNA platform owner”. 2. Moderna Why they might be interested: The entire company is built on RNA technology. They are actively looking for the next generation after mRNA. Circular RNA can have: longer stability longer protein production lower dose If circRNA proves stronger than mRNA in some applications, Moderna would almost be forced to acquire the technology quickly. 3. Roche Why Roche makes strategic sense: They invest heavily in gene therapy. They have many programs where protein expression is central. circRNA can potentially be used for in-vivo protein production. Roche has previously acquired smaller biotech platforms to strengthen their pipeline.
- 1 t sitten1 t sitten"Be greedy when others are fearful" Warren buffett. 😉
- ·1 t sittenThe last time we got news was on February 26th when it rose from 2.2 to 3.5 in a short time. There was a lot of hype around the stock which made it rise significantly. Now that time passes without news, it will naturally fall, as many simply take profit and sell off. But the most important thing is that despite no news for some time, we are at 3, which is still an increase of 36% since the last news. It can easily fall further in the next couple of days. Personally, I see it as a cheap buying opportunity. It will be exciting to hear what CEO Erik Wiklund has to say on the podcast on March 17th, and if things go well on March 18th at the LSX RNA Leaders Europe conference, I cannot see how the stock should fall next week. It is important to understand, however, that this stock is dependent on news, so if there are periods without news, it will fall, and then it's just about having patience.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 490 | - | - | ||
| 10 | - | - | ||
| 1 | - | - | ||
| 4 725 | - | - | ||
| 6 542 | - | - |
Välittäjätilasto
Dataa ei löytynyt